Management of Febrile Neutropenia
Initial Assessment and Risk Stratification
- The American College of Physicians recommends that febrile neutropenia be defined as a single oral temperature ≥38.3°C or ≥38.0°C for 1 hour with ANC ≤500 cells/mm³, and requires urgent empirical broad-spectrum antibiotics within the first hour of presentation 1
- Severe neutropenia requiring urgent intervention is defined as ANC ≤500 cells/mm³, or ANC ≤1,000 cells/mm³ with predicted decrease to ≤500 cells/mm³ 1
- Critical thresholds for neutropenia include ANC <500 cells/mm³, which is associated with a high risk for serious bacterial infections 1, 3
- ANC <100 cells/mm³ is associated with the highest risk, with >20% of patients developing bacteremia 3
Management of Febrile Neutropenia
- The Infectious Diseases Society of America recommends starting empirical intravenous broad-spectrum antibiotics immediately in high-risk patients with febrile neutropenia 1, 2
- Recommended regimens include monotherapy with antipseudomonal beta-lactam (cefepime, ceftazidime, carbapenem, or piperacillin-tazobactam) or dual therapy with antipseudomonal beta-lactam plus aminoglycoside 1
- Low-risk patients with febrile neutropenia may use oral antibiotics, such as ciprofloxacin plus amoxicillin-clavulanate, after initial 48 hours of IV therapy if stable 1, 3
- The duration of antibiotic therapy should be based on the patient's clinical presentation, with afebrile patients stopping antibiotics 48 hours after becoming afebrile 1, 3
Monitoring and Support
- The American Society of Clinical Oncology recommends obtaining two sets of blood cultures from peripheral vein and any indwelling catheters before starting antibiotics 4
- Urgent laboratory tests, including complete blood count with differential, renal and liver function, coagulation screen, and C-reactive protein, should be performed in patients with febrile neutropenia 4
- Imaging, including chest radiograph and CT scanning, should be performed as needed to evaluate for infection foci 2, 4
- G-CSF (filgrastim) should be considered in cases with predicted worsening course, with a recommended dose of 5 mcg/kg/day subcutaneously for chemotherapy-induced neutropenia 1, 3
- Trimethoprim-sulfamethoxazole should be used for Pneumocystis prophylaxis in prolonged neutropenia 1, 3